Susanne Bonekamp1, David Bonekamp1, Jean Francois Geschwind2, Celia Pamela Corona-Villalobos1, Vivek Gowdra Halappa2, Luciana Athayde2, Neda Rastegar2, Ihab R. Kamel2
1Radiology, Johns Hopkins University, Baltimore, MD, United States; 2Radiology, JHU, Baltimore, MD, United States
Assessing early response to intra-arterial treatment is paramount for clinical care in patients with unresectable Hepatocellular Carcinoma. The arterial enhancement fraction (AEF), a surrogate measure of the hepatic perfusion index, was measured using tri-phase MRI data. AEF response after the first intra-arterial treatment session was associated with improved survival and provided a better stratification of patients into responders and non-responders than currently employed treatment response metrics (RECIST, EASL).